HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling

Oncogene

Volumn 32, Issue 35, 2013, Pages 4169-4180

  Hartman, Z ^a   Zhao, H ^a   Agazie, Y M ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

autophosphorylation; EGFR; HER2; signaling; tumorigenesis

Indexed keywords

ADAPTOR PROTEIN; CBL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; LIGAND; PHOSPHOLIPASE C GAMMA;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; BINDING SITE; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; DEGRADATION; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GRB2 ADAPTOR PROTEIN; HUMANS; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS C-CBL; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 84883489054     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.418     Document Type: Article

References (55)

1. Dionne CA, Jaye M, Schlessinger J. Structural diversity and binding of FGF receptors. Ann N Y Acad Sci 1991; 638: 161-166.
2. Johnson DE, Williams LT. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 1993; 60: 1-41.
3. Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984; 309: 418-425.
4. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 2003; 11: 495-505.
5. Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon MA. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 2003; 11: 507-517.
6. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 2002; 110: 763-773.
7. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002; 110: 775-787.
8. Badache A, Goncalves A. The ErbB2 signaling network as a target for breast cancer therapy. J Mammary Gland Biol Neoplasia 2006; 11: 13-25.
9. Carlsson J, Nordgren H, Sjostrom J, Wester K, Villman K, Bengtsson NO et al. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 2004; 90: 2344-2348.
10. Fukushige S, Matsubara K, Yoshida M, Sasaki M, Suzuki T, Semba K et al. Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol 1986; 6: 955-958.
11. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985; 229: 974-976.
12. Pawson T, Gish GD. SH2 and SH3 domains: from structure to function. Cell 1992; 71: 359-362.
13. Feng GS, Shen R, Heng HH, Tsui LC, Kazlauskas A, Pawson T. Receptor-binding tyrosine phosphorylation and chromosome localization of the mouse SH2-containing phosphotyrosine phosphatase Syp. Oncogene 1994; 9: 1545-1550.
14. Hadari YR, Kouhara H, Lax I, Schlessinger J. Binding of Shp2 tyrosine phosphatase to FRS2 is essential for fibroblast growth factor-induced PC12 cell differentiation. Mol Cell Biol 1998; 18: 3966-3973.
15. Lechleider RJ, Sugimoto S, Bennett AM, Kashishian AS, Cooper JA, Shoelson SE et al. Activation of the SH2-containing phosphotyrosine phosphatase SH-PTP2 by its binding site, phosphotyrosine 1009, on the human platelet-derived growth factor receptor. J Biol Chem 1993; 268: 21478-21481.
16. Schlessinger J, Mohammadi M, Margolis B, Ullrich A. Role of SH2-containing proteins in cellular signaling by receptor tyrosine kinases. Cold Spring Harb Symp Quant Biol 1992; 57: 67-74.
17. Agazie YM, Hayman MJ. Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. Mol Cell Biol 2003; 23: 7875-7886.
18. Baldys A, Gooz M, Morinelli TA, Lee MH, Raymond Jr JR, Luttrell LM et al. Essential role of c-Cbl in amphiregulin-induced recycling and signaling of the endogenous epidermal growth factor receptor. Biochemistry 2009; 48: 1462-1473.
19. Bollag G, McCormick F. Differential regulation of rasGAP and neurofibromatosis gene product activities. Nature 1991; 351: 576-579.
20. Ekman S, Thuresson ER, Heldin CH, Ronnstrand L. Increased mitogenicity of an alphabeta heterodimeric PDGF receptor complex correlates with lack of RasGAP binding. Oncogene 1999; 18: 2481-2488.
21. Jiang X, Sorkin A. Epidermal growth factor receptor internalization through clathrin-coated pits requires Cbl RING finger and proline-rich domains but not receptor polyubiquitylation. Traffic 2003; 4: 529-543.
22. Pamonsinlapatham P, Hadj-Slimane R, Lepelletier Y, Allain B, Toccafondi M Garbay C et al. P120-Ras GTPase activating protein (RasGAP): a multi-interacting protein in downstream signaling. Biochimie 2009; 91: 320-328.
23. Scheffzek K, Ahmadian MR, Kabsch W, Wiesmuller L, Lautwein A, Schmitz F et al. The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 1997; 277: 333-338.
24. Beguinot L, Lyall RM, Willingham MC, Pastan I. Down-regulation of the epidermal growth factor receptor in KB cells is due to receptor internalization and subsequent degradation in lysosomes. Proc Natl Acad Sci USA 1984; 81: 2384-2388.
25. Helin K, Beguinot L. Internalization and down-regulation of the human epidermal growth factor receptor are regulated by the carboxyl-terminal tyrosines. J Biol Chem 1991; 266: 8363-8368.
26. Sorkin A, Di Fiore PP, Carpenter G. The carboxyl terminus of epidermal growth factor receptor/erbB-2 chimerae is internalization impaired. Oncogene 1993; 8: 3021-3028.
27. Sorkin A, Goh LK. Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 2009; 315: 683-696.
28. Huang G, Chantry A, Epstein RJ. Overexpression of ErbB2 impairs ligand-dependent downregulation of epidermal growth factor receptors via a post-transcriptional mechanism. J Cell Biochem 1999; 74: 23-30.
29. Worthylake R, Opresko LK, Wiley HS. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 1999; 274: 8865-8874.
30. Zhou X, Agazie YM. The signaling and transformation potency of the overexpressed HER2 protein is dependent on the normally-expressed EGFR. Cell Signal 2012; 24: 140-150.
31. Hendriks BS, Wiley HS, Lauffenburger D. HER2-mediated effects on EGFR endosomal sorting: analysis of biophysical mechanisms. Biophys J 2003; 85: 2732-2745.
32. Muthuswamy SK, Gilman M, Brugge JS. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo-and heterodimers. Mol Cell Biol 1999; 19: 6845-6857.
33. Jiang X, Huang F, Marusyk A, Sorkin A. Grb2 regulates internalization of EGF receptors through clathrin-coated pits. Mol Biol Cell 2003; 14: 858-870.
34. Sun J, Pedersen M, Bengtsson S, Ronnstrand L. Grb2 mediates negative regulation of stem cell factor receptor/c-Kit signaling by recruitment of Cbl. Exp Cell Res 2007; 313: 3935-3942.
35. Longva KE, Blystad FD, Stang E, Larsen AM, Johannessen LE, Madshus IH. Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J Cell Biol 2002; 156: 843-854.
36. Aertgeerts K, Skene R, Yano J, Sang BC, Zou H, Snell G et al. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. J Biol Chem 2011; 286: 18756-18765.
37. Fan YX, Wong L, Ding J, Spiridonov NA, Johnson RC, Johnson GR. Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism. J Biol Chem 2008; 283: 1588-1596.
38. Morandell S, Stasyk T, Skvortsov S, Ascher S, Huber LA. Quantitative proteomics and phosphoproteomics reveal novel insights into complexity and dynamics of the EGFR signaling network. Proteomics 2008; 8: 4383-4401.
39. Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 2006; 12: 7242-7251.
40. Fragale A, Tartaglia M, Wu J, Gelb BD. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum Mutat 2004; 23: 267-277.
41. Meng S, Chen Z, Munoz-Antonia T, Wu J. Participation of both Gab1 and Gab2 in the activation of the ERK/MAPK pathway by epidermal growth factor. Biochem J 2005; 391: 143-151.
42. Ravichandran KS, Lorenz U, Shoelson SE, Burakoff SJ. Interaction of Shc with Grb2 regulates the Grb2 association with mSOS. Ann N Y Acad Sci 1995; 766: 202-203.
43. Russo C, Dolcini V, Salis S, Venezia V, Violani E, Carlo P et al. Signal transduction through tyrosine-phosphorylated carboxy-terminal fragments of APP via an enhanced interaction with Shc/Grb2 adaptor proteins in reactive astrocytes of Alzheimer's disease brain. Ann N Y Acad Sci 2002; 973: 323-333.
44. Schulze WX, Deng L, Mann M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 2005; 1: 0001-0008.
45. Monsey J, Shen W, Schlesinger P, R Bose. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system. J Biol Chem 2010; 285: 7035-7044.
46. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006; 125: 1137-1149.
47. Yamanashi Y, Tezuka T, Yokoyama K. Activation of receptor protein-tyrosine kinases from the cytoplasmic compartment. J Biochem. 151: 353-359.
48. Zhou X, Agazie YM. Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation. J Biol Chem 2009; 284: 12226-12234.
49. Sperka T, Geissler KJ, Merkel U, Scholl I, Rubio I, Herrlich P et al. Activation of Ras requires the ERM-dependent link of actin to the plasma membrane. PLoS One 2011; 6: e27511.
50. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008; 68: 5878-5887.
51. Rana P, Sridhar SS. Efficacy and tolerability of lapatinib in the management of breast cancer. Breast Cancer (Auckl) 6: 67-77.
52. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003; 30: 256-268.
53. Agazie YM, Movilla N, Ischenko I, Hayman MJ. The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3. Oncogene 2003; 22: 6909-6918.
54. Yuan YL, Zhou XH, Song J, Qiu XP, Li J, Ye LF. Dual silencing of type 1 insulin-like growth factor and epidermal growth factor receptors to induce apoptosis of nasopharyngeal cancer cells. J Laryngol Otol 2008; 122: 952-960.
55. Duan L, Miura Y, Dimri M, Majumder B, Dodge IL, Reddi AL et al. Cbl-mediated ubiquitinylation is required for lysosomal sorting of epidermal growth factor receptor but is dispensable for endocytosis. J Biol Chem 2003; 278: 28950-28960.